Protocol Ledger

NCT03338023 · Phase III · COMPLETED

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Interventional Phase III clinical trial protocol NCT03338023 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-23 Enrollment: 272 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03338023
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)272 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03338023
Protocol FieldVerified Registry Value
NCT IdentifierNCT03338023
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment272 participants (ACTUAL)
Registered Start Date2018-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI